Metformin Cough: FDA Data Shows 2.25% Incidence Rate
FDA-based trial data links cough to 2.25% of metformin users, alongside GI effects in 20-53% and B12 deficiency risk after long-term use.
6 source-based articles maintained by the HealthRX.com Editorial Team.

Showing 6 of 6 clinical reviews.
FDA-based trial data links cough to 2.25% of metformin users, alongside GI effects in 20-53% and B12 deficiency risk after long-term use.
A clinical review of metformin's delayed-onset adverse effects, including lactic acidosis risk, vitamin B12 depletion, GI intolerance patterns, and when to escalate care.
A clinical breakdown of metformin adverse events by severity grade, organ system, and patient phenotype, with data from UKPDS, FAERS, and post-market literature to guide prescribing decisions.
A guide to metformin's potentially permanent side effects, including B12 deficiency, lactic acidosis risk, and long-term kidney considerations, with cited trial data and dosing guidance.
A guide to the rare but serious adverse events linked to metformin, including lactic acidosis, vitamin B12 deficiency, severe hypoglycemia, and hepatotoxicity. Includes trial data, FAERS reports, and clinical thresholds.
There's no true withdrawal syndrome, but stopping metformin can trigger rebound blood sugar rises within 48 to 72 hours. See tapering steps and GI effect data.